Literature DB >> 11032897

Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.

T Rubino1, D Viganò, P Massi, D Parolaro.   

Abstract

Chronic exposure to CP55,940 produced a significant down-regulation of cannabinoid receptors in the striatum, cortex, hippocampus, and cerebellum of rat brain. At 24 h after SR141716-precipitated withdrawal, we observed a tendency to return to basal levels in the striatum and cortex, whereas the specific binding remained lower in the hippocampus and cerebellum. When we surveyed cannabinoid receptor-activated G proteins, in chronic CP55,940-treated rats the guanosine 5'-O:-(3-[(35)S]thiotriphosphate) ([(35)S]GTPgammaS) binding assay revealed a decrease of activated G proteins in the striatum, cortex, and hippocampus, whereas no significant changes were seen in the cerebellum. At 24 h after the SR141716-precipitated withdrawal, [(35)S]GTPgammaS binding increased compared with that of rats chronically exposed to CP55,940, attaining the control level except for cerebellum, where we observed a trend to overcome the control amounts. Concerning the cyclic AMP (cAMP) cascade, which represents the major intracellular signaling pathway activated by cannabinoid receptors, in the cerebral areas from rats chronically exposed to CP55,940 we found alteration in neither cAMP levels nor protein kinase A activity. In the brain regions taken from CP55, 940-withdrawn rats, we only observed a significant up-regulation in the cerebellum. Our findings suggest that receptor desensitization and down-regulation are strictly involved in the development of cannabinoid tolerance, whereas alterations in the cAMP cascade in the cerebellum could be relevant in the mediation of the motor component of cannabinoid abstinence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032897     DOI: 10.1046/j.1471-4159.2000.0752080.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation.

Authors:  E Zamberletti; F Piscitelli; F Cadeddu; T Rubino; W Fratta; P Fadda; V Di Marzo; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 2.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

3.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

4.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

5.  Lifelong imbalanced LA/ALA intake impairs emotional and cognitive behavior via changes in brain endocannabinoid system.

Authors:  Erica Zamberletti; Fabiana Piscitelli; Valentina De Castro; Elisabetta Murru; Marina Gabaglio; Paola Colucci; Chiara Fanali; Pamela Prini; Tiziana Bisogno; Mauro Maccarrone; Patrizia Campolongo; Sebastiano Banni; Tiziana Rubino; Daniela Parolaro
Journal:  J Lipid Res       Date:  2016-11-30       Impact factor: 5.922

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.

Authors:  J J McDougall; V Yu; J Thomson
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

8.  Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  Synapse       Date:  2012-12-08       Impact factor: 2.562

Review 9.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

10.  Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.

Authors:  Stephen M Eggan; Takanori Hashimoto; David A Lewis
Journal:  Arch Gen Psychiatry       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.